血压变化与原发性阿尔多斯特主义患者的损伤之间的关联
Siying Wu1, Sen Li1, Jing Huang1
1Department of Cardiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
概括
与基本高血压相比,原发性阿尔多斯特龙症 (PA) 患者的损伤标志物增加和血压变化 (BPV) 模式明显明显. 管理PA需要解决代谢因素,BPV和脏健康,以获得更好的结果.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 心脏病学 心脏病学
背景情况:
- 原发性阿尔多斯特隆症 (PA) 与心血管和脏风险的增加有关.
- 了解血压变化 (BPV) 对PA中损伤的具体影响至关重要.
- 基本高血压 (EH) 作为BPV和PA中的标记物的比较.
研究的目的:
- 为了研究BPV和PA患者的损伤之间的关联.
- 为了比较PA和EH队列之间的BPV和脏标志物.
- 确定PA中功能 (eGFR) 和损伤 (UACR) 的决定因素.
主要方法:
- 门诊血压监测 (ABPM) 用于129名PA患者和EH对照.
- 测量包括囊素C,尿中微专蛋白/肌素比率 (UACR) 和各种BPV指数.
- 多重线性回归分析确定了eGFR和UACR的决定因素.
主要成果:
- 胰腺癌患者的囊素C和UACR含量较高,非浸泡模式较多.
- 在PA中,24小时加权透气血压的标准偏差在PA中较低.
- 高血压持续时间,血管新生素II和白天心性BPV影响了EGFR;24小时心性BPV强烈预测了UACR.
结论:
- 胰腺炎与明显的BPV特征和增加的损伤标志物有关.
- 24小时的缩血压变化是PA中脏损伤的重要预测因素.
- 综合管理PA应解决代谢,BPV和脏健康问题.
相关概念视频
01:18Hypertension and Regulation of Blood Pressure
2.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
606
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
606
01:33Hormonal Regulation
33.1K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
33.1K
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
621
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
621
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
716
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
716
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422